Welcome to our dedicated page for Azitra news (Ticker: AZTR), a resource for investors and traders seeking the latest updates and insights on Azitra stock.
Azitra, Inc. (NYSE American: AZTR) is a clinical stage biopharmaceutical company developing therapies for precision dermatology, and its news flow reflects the progress and challenges of an emerging biotechnology issuer. Company announcements frequently highlight updates on its lead program, ATR-12, which uses an engineered strain of Staphylococcus epidermidis to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. News items also cover milestones for ATR-04, an engineered S. epidermidis program for EGFR inhibitor (EGFRi)–associated rash and skin toxicity, and ATR-01, a preclinical program designed to treat ichthyosis vulgaris through filaggrin secretion.
Investors following AZTR news can expect regular coverage of clinical trial milestones, such as initiation of Phase 1b and Phase 1/2 studies, first-patient-dosed events, and the presentation of preclinical and clinical data at scientific and investor conferences. The company’s releases describe participation in events like BIO-Europe, Biotech Showcase, and investment conferences, where management discusses safety data, pharmacology results, and development strategy for ATR-12, ATR-04, and ATR-01.
News about Azitra also includes regulatory and listing developments, including notices from NYSE American regarding compliance with continued listing standards and acceptance of the company’s plan to regain compliance by a specified deadline. Additional articles cover capital markets activity, such as private placements, equity line of credit transactions, and related registration statements and proxy proposals tied to share issuances and warrants.
By monitoring this AZTR news page, readers can track how Azitra advances its live biotherapeutic and engineered protein programs in dermatology, how it responds to stock exchange compliance requirements, and how it structures financings to support ongoing clinical and preclinical work.
Azitra (NYSE American: AZTR) will present at Biotech Showcase in San Francisco on January 13, 2026 at 2:30 PM PT. Management will hold one-on-one meetings with registered investors and potential partners to review the company's clinical development strategy, recent corporate achievements, and anticipated milestones.
The presentation will be delivered by Travis Whitfill, Chief Operating Officer, at the Hilton San Francisco Union Square (Yosemite C, Ballroom Level). Registration is available through the event website for accredited attendees.
Azitra (NYSE: AZTR) received NYSE American staff approval of its listing standards compliance plan under Section 1003(a)(ii).
Azitra previously received a notice for not meeting the $4.0 million minimum stockholders' equity requirement after reporting losses in three of the last four fiscal years. The company must regain compliance by April 1, 2027 or face potential delisting. Azitra will remain listed during monitoring and is exploring multiple funding avenues to achieve compliance.
Azitra (NYSE American: AZTR) entered a private placement with a single institutional investor to sell 4,687,500 shares of common stock (or pre-funded warrants in-lieu) together with warrants to purchase up to 4,687,500 shares.
The combined effective offering price per share plus warrant is $0.32, producing estimated gross proceeds of approximately $1.5 million before placement agent fees and expenses. The warrants have an exercise price of $0.32, will be exercisable upon shareholder approval, and expire five years after that approval. The Offering is expected to close on or about November 25, 2025. Maxim Group is sole placement agent. The company has agreed to file a resale registration statement with the SEC.
Azitra (NYSE American: AZTR) reported Q3 2025 results and business updates on Nov 12, 2025. Key operational highlights: dosed first patient in the Phase 1/2 ATR-04 trial for EGFRi-associated rash (Aug 2025) and presented positive preclinical data for ATR-01 at BIO-Europe. The company raised $2.8M under an equity line with Alumni Capital LP. Financials: R&D expense was $1.2M (Q3 2025) vs $1.0M (Q3 2024); G&A was $1.6M vs $1.9M; net loss was $2.8M vs $1.0M; cash and cash equivalents were $1.4M as of Sept 30, 2025.
The company said it continues to advance ATR-12, ATR-04, and ATR-01 programs derived from its topical live biotherapeutic platform.
Azitra (NYSE American: AZTR) on Nov. 7, 2025 denied a circulated report that it had priced a $44 million registered direct offering. The company said the report is false and urged investors to rely only on information issued through its official channels. Azitra also said it is taking steps to identify the source of the false report.
Azitra (NYSE: AZTR) announced positive preclinical results for ATR-01 (ATR01-616), an engineered S. epidermidis strain designed to secrete functional human filaggrin to treat ichthyosis vulgaris.
Key findings reported: ATR01-616 secreted functional filaggrin in vitro, delivered filaggrin through the human stratum corneum (delivery below the barrier, p < 0.05), and significantly reduced transepidermal water loss in a damaged pig skin model (p < 0.002).
Azitra plans a path toward first-in-human studies and aims to submit an IND in 2026; detailed data will be presented at BIO-Europe, November 3–5, 2025.
Azitra (NYSE American: AZTR) announced that Travis Whitfill, Ph.D., co-founder and COO, will appear on a Dermatologic Rare Disease Panel at the Maxim Growth Summit in New York City on October 22, 2025 at 8:30 AM EDT.
The panel will discuss Netherton syndrome and Recessive Epidermolysis Bullosa (RDEB). Azitra's lead program, ATR-12, is in a Phase 1b trial in adult Netherton syndrome patients and uses an engineered strain of S. epidermidis to deliver LEKTI topically. Azitra also highlighted ATR-04, an engineered S. epidermidis program for EGFR inhibitor associated rash with FDA Fast Track designation and an open IND.
Azitra (NYSE American: AZTR) received a notice of non-compliance from NYSE American on October 3, 2025 under Section 1003(a)(ii).
The rule requires listed companies with recent losses to have $4 million or more in stockholders' equity. Azitra has until October 31, 2025 to file a Plan to regain compliance by April 1, 2027. The company says it will timely submit a Plan, is exploring multiple funding avenues, and intends to complete one or more transactions to achieve compliance. Receipt of the notice does not affect current listing or trading or SEC reporting.
Azitra is a clinical-stage dermatology company with lead programs ATR-12 (Phase 1b) and ATR-04 (FDA Fast Track; open IND) and a microbial library of ~1,500 strains.
Azitra (NYSE American: AZTR), a clinical stage biopharmaceutical company specializing in precision dermatology, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. Chief Operating Officer Travis Whitfill will deliver a virtual presentation on September 8, 2025, at 7:00 AM ET.
The presentation will highlight recent developments, including promising safety results from the Phase 1b trial of ATR-12 for Netherton syndrome and the initiation of patient dosing in the Phase 1/2 trial of ATR-04 for EGFR inhibitor-associated dermal toxicity. Dr. Whitfill will also conduct one-on-one meetings with investors and potential partners during the conference.
Azitra (NYSE American: AZTR) has initiated dosing in a Phase 1/2 clinical trial for ATR04-484, a topical live biotherapeutic treatment targeting EGFR inhibitor (EGFRi)-associated rash. The condition affects approximately 150,000 people annually in the U.S. and has received FDA Fast Track designation.
The multicenter, randomized, double-blind, vehicle-controlled study (NCT06830863) will evaluate ATR04-484's safety and tolerability in adult patients. The treatment addresses a critical medical need, as EGFRi-associated rash affects 50-80% of cancer patients receiving EGFR inhibitor treatments, often leading to cancer treatment interruption or discontinuation.
ATR04-484 is derived from a specially engineered Staphylococcus epidermidis strain, designed to reduce IL-36γ and S. aureus levels, which are elevated in affected patients.
FAQ
What is the current stock price of Azitra (AZTR)?
What is the market cap of Azitra (AZTR)?
